Publications

Adherence to and determinants of guideline-recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: insights from routine practice →

Lau-Min, KS, Li, Y, Eads, JR, Wang, X, Meropol, NJ, Mamtani, R, Getz, KD

March 2021

Manuscript

Cancer

Flatiron-authored

Real-world treatment patterns and outcomes in patients receiving second-line therapy for advanced/metastatic esophageal squamous cell carcinoma →

Abraham, P, Gricar, J, Zhang, Y, Shankaran, V

June 2020

Manuscript

Advances in Therapy

Pan-cancer profiling of the effect of biopsied site on tumor mutational burden measurements in a real-world data cohort →

Papillon-Cavanagh, S, Gao, C, Han, GC, Walsh, AM

May 2020

Abstract

AACR Annual Meeting

Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts) →

Stein, S, Snider, J, McCusker, M, Miksad, RA, Alexander, BM, Castellanos, EH, Backenroth, D, Schrock, AB, Madison, R, Carson, KR, Ali, SM

January 2020

Abstract

ASCO GI Symposium

Flatiron-authored

Real-world outcomes of first-line U.S. patients with unresectable advanced or metastatic gastroesophageal adenocarcinoma by primary tumor location →

Shankaran, V, Xiao, H, Bertwistle, D, Zhang, Y, Abraham, P, Chau, I

January 2020

Abstract

ASCO GI Symposium

Real-world treatment patterns and clinical outcomes across lines of therapy in patients with advanced/metastatic gastric or gastroesophageal junction cancer →

Le, DT, Ott, PA, Korytowsky, B, Le, H, Le, TK, Zhang, Y, Maglinte, GA, Abraham, P, Patel, D, Shangguan, T, Chau, I

September 2019

Manuscript

Clinical Colorectal Cancer

Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer →

Chau I, Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Sanchez T, Maglinte GA, Laurie M, Abraham P, Patel D, Shangguan T

September 2019

Manuscript

Gastric Cancer

Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab →

Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I

July 2019

Manuscript

Journal of Clinical Oncology

Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment →

Adamson B, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Organ dysfunction and clinical outcomes in patients treated with immune checkpoint inhibitors →

Liu Q, Sharon E, Zineh I, Xie D, Baxi SS, Liu C, Zhi J, Torres AZ, Gossai A, Sridhara R, Booth B, Blumenthal GM, Huang S-M, Khozin S

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Improving the Accuracy of Measuring Duration of Therapy by Identifying Patients Who Remain on Treatment in a Real-World Database →

Zhu Y, Hess LM

May 2019

Abstract

ISPOR Annual Meeting

Real-world outcomes and factors associated with the second-line treatment of patients with gastric, gastroesophageal junction, or esophageal adenocarcinoma →

Barzi A, Hess LM, Zhu YE, Liepa AM, Sugihara T, Beyrer J, Chao J

May 2019

Manuscript

Cancer Control

Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab →

Moser J, Solomon B, Nevala-Plagemann CD, Gilcrease GW, Whisenant JR, Garrido-Laguna I

January 2019

Abstract

ASCO GI Symposium

Comparative effectiveness of nivolumab relative to standard of care for advanced/metastatic gastric or gastroesophageal junction cancer: A simulated treatment comparison →

Chau I, Ayers D, Goring S, Keeping S, Goulding R, Cope S, Chamot E, Le H, Xu Y, Abraham P, Korytowsky B

January 2019

Abstract

ASCO GI Symposium

Real-World Outcomes and Patient (pt) Characteristics for the Second-Line (2L) Treatment of Gastric, Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma (EGAC) →

Barzi A, Hess L, Zhu Y, Liepa A, Fang Y, Kuder C, Beyrer J, Chao J

June 2018

Abstract

ASCO Annual Meeting

What is the Outcome of Receiving Subsequent Therapy among Patients (pts) with Advanced/Metastatic (Adv/Met) Gastric or Gastroesophageal Junction Cancer (GC/GEJC)? Experience from Electronic Health Records (EHR) →

Le DT, Janjigian YY, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Maglinte G, Patel D, Shangguan T, Chau I

June 2018

Abstract

ASCO Annual Meeting

Prevalence of Microsatellite Instability and Association with Pembrolizumab (P) Usage in a Real-World Clinico-Genomic Database →

O'Connell C, Backenroth D, Singal G, Agarwala V, Li G, Kaushik G, Alpha-Cobb G, Kao CK, Miller V, Abernethy AP, Carson K

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Survival of Chemotherapy (chemo) Refractory Gastric or Gastroesophageal Junction Cancer (GC/GEJC) Patients From Flatiron Health (FH): Matched Clinical Characteristics to ATTRACTION-2 and CHECKMATE-032 →

Janjigian YY, Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Sanchez T, Maglinte G, Laurie M, Patel D, Shangguan T, Chau I

January 2018

Abstract

ASCO Gastrointestinal Cancers Symposium

Treatment and Outcomes of Patients with Advanced Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma in the United States →

Barzi A, Hess L, Zhu Y, Liepa A, Fang Y, Kuder C, Beyrer J, Chao J

September 2017

Abstract

ESMO Annual Congress

Treatment and outcomes of patients with advanced gastric, esophageal, or gastroesophageal junction adenocarcinoma in the United States →

Barzi, A, Hess, LM, Zhu, YE, Liepa, AM, Fang, Y, Kuder, C, Beyrer, J, Chao, J

June 2017

Abstract

ESMO World Congress on Gastrointestinal Cancer